Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of specialized radiation therapy in treating patients with stage II, stage III, stage IV, or recurrent non-small cell lung cancer and poor performance status.
Checked against the public recordLast updated Aug 20, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- University of Texas Southwestern Medical Center
- Interventions being studied
- Radiation: hypofractionated radiation therapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer * Stage II-IV and/or recurrent disease * No small cell histology * Measurable or evaluable disease * Tumor not amenable to surgical resection * Tumor not eligible for stereotactic body radiation therapy * No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields PATIENT CHARACTERISTICS: * Zubrod performance status 2-4 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must agree to use effective contraception * Must complete all required pretreatment evaluations PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 1 week since prior chemotherapy or chemoradiation therapy * No concurrent chemotherapy * No other concurrent antineoplastic therapy (including standard-fractionated radiotherapy to the chest, chemotherapy, biological therapy, vaccine therapy, and surgery) 1 week before, during, and for 1 week after completion of study therapy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford UniversityStanford, California
- University of Texas Southwestern Medical CenterDallas, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 20, 2020. Always confirm current availability with the study team.